La cadena de opciones muestra datos clave de las opciones de acciones de Avenue Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Avenue Therapeutics..

Avenue Therapeutics (OTC:ATXI) Bolsa, Cadena de Opciones

Avenue Therapeutics

Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its current product candidates include AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's Disease), intravenous tramadol (IV tramadol) for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGMH

ANTE

ARBE

ARLO

ATXI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

FINV

GNPX

GRAB

HNRG

HROW

HYPR

KTCC

VRPX

VSTM

Las acciones de Harrow subieron un 23,1% en el premercado. Descubre qué otras compañías están ganando y perdiendo antes de la apertura.

Las acciones de Harrow (HROW) se disparan un 23%; aquí están 20 acciones que se mueven en el premercado

AVENUE THERAPEUTICS INC by Avenue Therapeutics, Inc.

Avenue Therapeutics Inc

Wells Fargo analyst Elyse Greenspan maintains Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) with a Overweight and raises the price target from $97 to $105.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Unum Gr, Raises Price Target to $105

Macro Economic Events

Econ #s

Economics

USA Redbook (YoY) 4.9% Vs 4.5% Prior

HSDT

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Wedbush analyst Daniel Ives reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and maintains $500 price target.

Reiteration

TSLA

Wedbush Reiterates Outperform on Tesla, Maintains $500 Price Target

Wedbush analyst Dan Ives predicts a weak performance for Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) amidst a fallout between CEO Elon Musk and President Donald Trump.
What Happened: On Tuesday, Ives posted on X his prediction about Tesla&#8217;s performance, attributing it to the strained relationship between Musk and Trump. He described the situation as a &#8220;junior high school friendship gone bad.&#8221; However, he added that it would eventually stabilize.
&#8220;At the end of the day Musk needs Trump and Trump needs Musk. Will settle down,&#8221; posted Ives.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Tesla to be weak this morning as the Street will show concern that the Trump and Musk once BFF relationship now backfires and turns into a junior high school friendship gone bad into an enemy. At the end of the day Musk needs Trump and Trump needs Musk. Will settle down &#x1f94a;&#x1f91d;
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1940022572625600815?ref_src=twsrc%5Etfw">July 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
SEE ALSO: <a href="https://benzinga.com/markets/macro-economic-events/25/07/46187826/mike-pences-advocacy-group-launches-campaign-to-extend-trumps-2017-tax-cuts-report" target="_blank" rel="noreferrer noopener">Mike Pence&#8217;s Advocacy Group Launches Campaign To Extend Trump&#8217;s 2017 Tax Cuts: Report</a>
Why It Matters: The relationship between Musk and Trump has been a topic of interest recently. Trump has been vocal about the subsidies Musk&#8217;s companies receive, suggesting that without them, Musk would have to &#8220;close up shop and head back home to South Africa.&#8221;
This public criticism by Trump has had an impact on Tesla&#8217;s stock. Following Trump&#8217;s comments, Tesla&#8217;s stock fell by <a href="https://www.benzinga.com/markets/tech/25/07/46189226/tesla-stock-falls-nearly-5-in-tuesday-pre-market-whats-going-on">nearly 5% </a>during the Tuesday pre-market session. Musk&#8217;s response to Trump&#8217;s spending bill also reignited political comeback rumors, further affecting the stock.
Investment advisor Ross Gerber criticized Tesla&#8217;s board for remaining silent amid the Trump-Musk Feud and the federal subsidies. He suggested that Musk&#8217;s enabling of Trump&#8217;s presidency would eventually lead to a power struggle.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/crypto/25/06/46186644/bitcoin-ethereum-dogecoin-slide-even-as-q2-turns-profitable-for-crypto-analyst-warns-about-decline-in-btc-if-the-apex-coin-doesnt-close-above-this-level" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Slide Even As Q2 Turns Profitable For Crypto: Analyst Warns About Decline In BTC If The Apex Coin Doesn&#8217;t Close Above This Level &#8211; Grayscale Bitcoin Mini Trust (BTC) Common</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tesla Stock Slump Tied To Trump-Musk 'Junior High School Friendship' Gone Sour, Says Dan Ives — But Predicts It Will 'Settle Down'

Wedbush analyst Daniel Ives reiterates Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) with a Outperform and maintains $75 price target.

PRGS

Wedbush Reiterates Outperform on Progress Software, Maintains $75 Price Target

Wells Fargo analyst Donald Fandetti maintains Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) with a Overweight and raises the price target from $65 to $75.

Wells Fargo Maintains Overweight on Synchrony Financial, Raises Price Target to $75

HURA

TuHURA Biosciences Added To Russell 3000 Index, With Automatic Inclusion In Russell 2000 Index

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival
2- and 6-week interim safety results demonstrated GRI-0621 to be safe and well-tolerated in the first 12 and 24 patients evaluated, respectively
Results on track for 6-week interim biomarker analysis (n=24) in July 2025 and topline data in Q3 2025
LA JOLLA, CA, July 01, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=baPDKYdp3BSWHP45JArGos_yUZqEn9JWMuXvfBdwYAxdL6IgP7Iji95uzky4X6ZrOY7DGAUopvYZfr1F87uU4g==">GRI Bio, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the completion of patient enrollment for its Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF").

Biotech

General

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Completes Enrollment In Phase 2a Trial Of GRI-0621 For Idiopathic Pulmonary Fibrosis; 2- And 6- Week Interim Safety Results Demonstrated GRI-0621 To Be Safe And Well-Tolerated In The First 12 And 24 Patients Evaluated, Respectively

New Era Helium, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEHC#NASDAQ">NEHC</a>) ("NEH" or the "Company"), a next-gen exploration and production platform in the Permian Basin, today announced that Texas Critical Data Centers LLC ("TCDC"), NEH's joint venture with Sharon AI, signed a non-binding Letter of Intent ("LOI") with a leading global provider of High Performance Cloud for AI and Modern Workloads, marking a major milestone in NEH's digital infrastructure strategy within the Permian Basin.
Under the terms outlined in the LOI, the joint venture contemplates the acquisition of land and a power purchase agreement for up to 250 megawatts of behind-the-meter electricity, purpose-built to support advanced data center operations and next generation compute infrastructure.

NEHC

New Era Helium's JV TCDC Signs Non-Binding LOI With Global Provider Of High Performance Cloud For AI And Modern Workloads For 250MW AI Data Center JV In Permian Basin

A federal court has sided with the U.S. Department of Health and Human Services (HHS), rejecting Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) effort to reshape its participation in the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">340B Drug Pricing Program</a>.
The ruling comes after months of legal back-and-forth following Johnson &amp; Johnson's proposal to shift from upfront drug discounts to a rebate model—an approach the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40560227/johnson-johnson-aims-new-policy-for-hospital-payments-under-340b-drug-discount-program-related-to" rel="noreferrer noopener">agency never formally approved</a>.
The dispute centers on the 340B Program, a federal initiative requiring pharmaceutical manufacturers that participate in Medicaid and Medicare Part B to sell outpatient drugs at reduced prices to certain healthcare providers, including hospitals and clinics that serve low-income and rural populations.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/46166652/fda-eases-access-to-life-saving-gene-therapies-for-blood-cancers" rel="noreferrer noopener">FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers</a>
Johnson &amp; Johnson, a long-time participant in the program, initiated litigation in November 2024 after the Health Resources and Services Administration (HRSA) declined to approve its proposed rebate structure.
Under Johnson &amp; Johnson&#8217;s plan, covered entities would pay the full list price for certain drugs and receive rebates later.
The company contacted HRSA in June 2024 to outline the plan, but the agency made clear it had not given the green light.
Despite this, Johnson &amp; Johnson <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs" rel="noreferrer noopener">proceeded to file suit</a> against HHS, HRSA, and their respective leadership, arguing that HRSA's rejection was arbitrary under the Administrative Procedure Act (APA).
In January 2025, UMass Memorial Medical Center, Genesis HealthCare System, and the advocacy group 340B Health were granted permission to intervene in the case as defendants, <a target="_blank" href="https://sponsors.aha.org/rs/710-ZLL-651/images/20250627_340B_045111473084.pdf?version=0" rel="noreferrer noopener">arguing</a> the rebate model would undercut the purpose of the 340B program and impose financial strain on safety-net providers.
Johnson &amp; Johnson subsequently moved for summary judgment on its single APA claim, while both the federal agencies and the intervenors filed cross-motions. The court has now denied Johnson &amp; Johnson's motion and ruled in favor of HHS and the intervenors, concluding that the agency acted within its authority and did not violate administrative law in rejecting the rebate plan.
The decision marks a significant win for hospitals and healthcare groups reliant on upfront 340B pricing to manage drug costs, especially for vulnerable patient populations. It also affirms HRSA's oversight authority in maintaining the integrity of the 340B program.
In sum, based on the plain and unambiguous language of the 340B statute, and supported by its purpose and history, HRSA has the authority to "provide" for discounts, rebates, or both. This conclusion defeats J&amp;J's claim that HRSA lacked the authority to require prior approval of J&amp;J's rebate model, the lawsuit alleged.
Price Action: JNJ stock is up 0.10% at $152.91 during the premarket session at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46021366/mark-cuban-corrects-elizabeth-warren-as-she-slams-jnj-pfe-for-higher-prices-and-zero-taxes-on-big-pharma-pbms-corrupt-healthcare" target="_blank" rel="noreferrer noopener">Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: &#8216;PBMs Corrupt Healthcare&#8217;</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

Legal

Johnson & Johnson's Drug Discount Plan Gets Thrown Out In Court

<a href="https://x.com/rachelvscott/status/1940021740677034098" title="https://x.com/rachelvscott/status/1940021740677034098">https://x.com/rachelvscott/status/1940021740677034098</a>

Politics

Senior Political Correspondent Covering The White House And Congress For ABC Rachel Scott Posts On X "NEW: I just asked the president about his July 4th deadline for Republicans - and whether he's open to moving it back. There are signs he is. 'I'd love to do July 4th but I think it's very hard to do July 4th…. I would say maybe July 4th or somewhere around there.'"

Sagtec Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) ("Sagtec" or the "Company"), a leading provider of customizable enterprise software solutions, today announced the signing of a US$10 million smart hospitality technology agreement with SMD Tech – FZCO, a UAE-based digital infrastructure firm. This major win represents a pivotal step in Sagtec's expansion strategy across the Middle East and its entry into the high-growth hotel automation segment.
Under the terms of the deal, Sagtec will develop and manage a next-generation Hotel Self Check-In/Out System across premium hospitality properties in the UAE. The project includes software licensing, systems integration, data analytics, and long-term service and maintenance, delivering an end-to-end solution that supports the region's push toward smart tourism and contactless guest experiences.
Contract Breakdown:
<ul>
<li>US$4 million – Licensing and custom software development</li>
<li>US$3 million – Five-year service and maintenance agreement</li>
<li>US$3 million – Five-year data hosting and analytics contract &nbsp;</li>
</ul>
Over 60% of The Contract Value Represents Multi-Year Recurring Revenue Streams
This latest development builds upon Sagtec's May 2025 announcement of a US$30 million revenue pipeline stemming from the exclusive distribution of its Speed+ Smart Ordering System. The UAE partnership diversifies Sagtec's SaaS verticals beyond Food &amp; Beverage into the rapidly growing hospitality tech domain.

Global

SAGT

Sagtec Global Signs $10M UAE Smart Hospitality Tech Deal To Expand Middle East Presence And Enter Hotel Automation Market

On Monday, Mesoblast Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) announced alignment with the U.S. Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor (rexlemestrocel-L) for ischemic heart failure with reduced ejection fraction <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">(HFrEF) and inflammation</a>.
In follow-up to the successful Type B meeting in early 2024 under the existing Regenerative Medicine Advanced Therapy (RMAT) designation for Revascor in end-stage HFrEF patients with a left ventricular assist device (LVAD), where the FDA stated that the results of the presented studies could support accelerated approval, Mesoblast met with FDA on June 3, 2025 to align <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46185666/mesoblast-and-fda-align-on-key-items-for-revascor-biologic-license-application-in-ischemic-heart-f" rel="noreferrer noopener">on key items for BLA filing</a>.
The FDA provided formal minutes to the company following the most recent Type B meeting. The minutes confirm alignment with FDA on chemistry, manufacturing &amp; controls (CMC) items, potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42572083/mesoblasts-cell-therapy-treatment-for-graft-versus-host-disease-gets-fda-approval-stock-surges" rel="noreferrer noopener">Mesoblast&#8217;s Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges</a>
Mesoblast intends to file for accelerated approval in patients with end-stage ischemic HFrEF implanted with an LVAD by the end of the year.
In other recent developments, Mesoblast received seven years of orphan-drug exclusive approval from the FDA for Ryoncil (remestemcel-L) for steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 <a href="https://www.benzinga.com/pressreleases/25/05/g45426923/fda-provides-seven-years-of-orphan-drug-exclusive-approval-for-ryoncil" target="_blank" rel="noreferrer noopener">months of age and older in May</a>.
This period of statutory exclusivity means that the FDA will not approve another mesenchymal stromal or stem cell (MSC) products for this indication during the 7 years from the approval of Ryoncil.
Separately, Mesoblast has biologic exclusivity preventing another sponsor from referencing the Ryoncil biologic license application (BLA) until December 2036, twelve years from its first approval which would prevent market entry by a biosimilar.
These statutory exclusivities, in addition to Mesoblast&#8217;s strong U.S. intellectual property position on MSC composition of matter, manufacturing, and indications, including SR-aGvHD, provide a commercial barrier to entry against competitors through 2044.
In early July, Mesoblast will meet with the FDA to discuss a pivotal trial of Ryoncil in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45896452/mesoblast-maintains-momentum-with-fda-on-accelerated-approval-pathway-for-revascor-in-ischemic-hea" rel="noreferrer noopener">adults with SR-aGvHD</a>.
This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN). The objective is to extend the product&#8217;s label from children to adults with SR-aGvHD.
Price Action: At the last check on Tuesday, MESO stock was up 8.82% at $11.85 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46189380/nvidias-chinese-rivals-look-to-cash-in-on-us-tech-ban-moore-threads-metax-plot-1-65-billion-ipo" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Chinese Rivals Look To Cash In On US Tech Ban: Moore Threads, MetaX Plot $1.65 Billion IPO</a></li>
</ul>
Photo by Tada Images via Shutterstock

MESO

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01010458/Unisound-0620-900x600-2-1.png" alt="" class="wp-image-15111" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01010458/Unisound-0620-900x600-2-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01010458/Unisound-0620-900x600-2-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01010458/Unisound-0620-900x600-2-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The provider of AI services for a wide range of business customers raised $41 million in its Hong Kong listing, and could raise more in the coming months with secondary share sales

By Doug Young
Unisound AI Technology Co. Ltd.&nbsp;(9678.HK) made its Hong Kong trading debut on Monday, offering investors a new artificial intelligence (AI) choice with a fully integrated product boasting a diverse customer base, speaking to its wide range of potential business users.
The company&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0627/2025062702974.pdf">raised</a>&nbsp;HK$206 million ($26 million) by selling 1.56 million shares for HK$205 apiece, with about a third of those going to three cornerstone investors. The shares for sale represented a relatively small 2.2% of its share capital, suggesting Unisound could sell more stock in one or more secondary offerings in the months ahead if demand is strong.
The stock opened flat at HK$205 when trading began, valuing the company at HK$14.5 billion.
Unisound is one of the older players on China's AI scene, founded more than a decade ago in 2012 by Huang Wei and Liang Jia'en, both of whom come from scientific backgrounds. Backed by strong technological capabilities and its accumulated research in speech recognition and cognitive intelligence, the company has developed dozens of vertically integrated AI products and solutions. These are primarily sold to enterprise clients across sectors such as healthcare and insurance, daily life services, and transportation.
Underpinning its AI services, which help customers run their business processes more efficiently, is Unisound's Atlas Infrastructure, which it began building in 2016. That's the foundation for UniGPT, a proprietary 60 billion-parameter large language model (LLM) that the company launched in 2023. UniGPT is the core algorithm for the company's customer-facing Unibrain central technology platform.
Unisound's revenue grew 29% last year to 939 million yuan ($131 million) from 727 million yuan in 2023. It breaks that figure into two main categories, healthcare and daily life. The daily life segment accounted for about 80% of its revenue last year, covering enterprise clients from the smart mobility and smart living sectors.
Notably, the company's top five customers accounted for just about a quarter of its revenue last year, a relatively low figure. That shows it has a large customer base – a relative rarity among some Chinese AI companies that often rely on just a small number of clients for most of their business.
The company's gross profit margin stood at a relatively high 38.8% last year. But its heavy R&amp;D spending, which is quite common for companies in the AI space, caused its adjusted net loss to widen by 22% last year to 168 million yuan from 137 million yuan in 2023. The company's cash also fell to 156 million yuan by the end of last year, though the new infusion of IPO funds should help as it sets its sights on eventually becoming profitable.
At its IPO price, the company trades at a price-to-sales (P/S) ratio of 14, which looks quite strong compared to some of its Hong Kong-listed peers. By comparison, the larger SenseTime (0020.HK) and Fourth Paradigm (6682.HK) trade at P/S multiples of 12 and 4.3, respectively.

Asia

IPOs

Opinion

Tech

Unisound's IPO offers Investors A New AI Choice

Wells Fargo analyst Jason Haas upgrades Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) from Underweight to Equal-Weight and raises the price target from $196 to $221.

Upgrades

CTAS

Wells Fargo Upgrades Cintas to Equal-Weight, Raises Price Target to $221

International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) announced on Tuesday an expansion of its relationship with database automation leader DBmaestro, marking a new original equipment manufacturer agreement aimed at strengthening<a href="https://www.benzinga.com/pressreleases/25/07/n46191636/ibm-and-dbmaestro-expand-strategic-oem-partnership-to-deliver-enterprise-grade-database-devops-and" target="_blank" rel="noreferrer noopener"> IBM&#8217;s enterprise DevOps capabilities</a>.
The agreement integrates DBmaestro&#8217;s platform into IBM&#8217;s software portfolio, providing customers with access to robust database DevSecOps tools and advanced observability features.
The partnership builds on IBM&#8217;s previous reseller relationship with DBmaestro and marks a significant milestone in the companies&#8217; collaboration.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46003044/ibms-rally-masks-under-ownership-analyst-sees-further-upside-potential" rel="noreferrer noopener">IBM Stock Remains Under-Owned Despite Rally, Analyst Sees Further Upside Potential</a>
Under this new arrangement, DBmaestro&#8217;s automation technology will become a native element in IBM DevOps solutions including IBM DevOps Loop, Deploy, and Velocity, with further integrations planned across platforms such as IBM Z, HashiCorp Vault, Instana, and more.
Through the OEM partnership, IBM customers can now manage database changes alongside application code, streamlining DevOps workflows. DBmaestro&#8217;s suite offers a range of capabilities, including version control, schema change automation, monitoring, analytics, and error detection, enhancing the end-to-end software delivery lifecycle.
The integration enables faster deployment cycles, tighter compliance controls, and real-time performance tracking.
It also introduces AI-driven insights, helping organizations proactively address errors and implement best practices.
According to DBmaestro CEO Gil Nizri, the joint offering allows enterprises to &#8220;orchestrate flawless software delivery from application code to database deployments.&#8221;
James Hunter, program director at IBM DevOps Automation, emphasized that DBmaestro&#8217;s inclusion will help eliminate one of the final obstacles to complete DevOps integration—databases.
&#8220;This partnership expansion empowers our customers to achieve faster, safer, and more reliable software delivery,&#8221; Hunter said in a statement.
Designed for hybrid and multi-cloud environments, the integrated solution supports agility across complex enterprise IT architectures, further aligning with IBM&#8217;s mission to support digital transformation at scale.
Price Action: IBM shares are trading higher by 0.10% to $295.06 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46189943/us-stock-futures-slip-after-two-days-of-record-advances-fomo-could-add-another-5-10-says-expert" target="_blank" rel="noreferrer noopener">US Stock Futures Slip After Two Days Of Record Advances: &#8216;FOMO Could Add Another 5%-10%…,&#8217; Says Expert</a></li>
</ul>
Photo: Shutterstock

Equities

IBM Just Tackled One Of Tech's Most Annoying Bottlenecks

Last week was, once again, dominated by geopolitical developments and commodity markets. While the global media headlines expected a deepening conflict between Israel and Iran, the spot oil price crashed.
The price movement demonstrated how commodity traders understand the world better than most, as <a href="https://oilprice.com/Energy/Oil-Prices/Oil-Prices-Crash-After-Iran-Strikes-US-Bases.html">oil dropped as much as 12.5%</a> on Monday, reaching around $68 per barrel, before closing the week at around $66. Gold also sank, reflecting the lower risk and a lack of hedging appetite, losing around 3.3% and closing at $3,274 per ounce.
This commodity price repositioning was more than enough to replace a news-light week for the forex market that has seen mixed results from eurozone PMI and Canadian and Australian CPI that ticked marginally higher than anticipated.
The week ahead will bring fewer geopolitical developments, but significant fundamental news, as heads of the Bank of Japan, the Bank of England, and the Federal Reserve will all speak on Tuesday. Thursday will bring the latest news about the Swiss CPI, potentially giving a green light to the return of negative interest rates. At the same time, the <a href="https://singaporeforexclub.com/what-is-the-nfp-in-forex">Non-Farm Payroll employment</a> data will arrive on Thursday, as the 4th of July holiday in the US falls on Friday.
<h2 class="wp-block-heading">Key News:</h2>
<ul class="wp-block-list">
<li>Tuesday: GBP – Governor Bailey Speech, JPY – Governor Ueda Speech, USD – Fed Chair Powell Speech, ISM Manufacturing PMI</li>
<li>Wednesday: USD – ADP Non-Farm Employment</li>
<li>Thursday: CHF – CPI m/m, USD – NFP, Unemployment, ISM Services PMI</li>
</ul>
<h2 class="wp-block-heading">Pairs In Focus</h2>
<h3 class="wp-block-heading">1. AUD SGD</h3>
This pair has been in a prolonged consolidation both on the daily and weekly charts, although the price action has started to turn bullish slowly.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="545" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01080649/AUDSGD-1024x545.png" alt="" class="wp-image-15126" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01080649/AUDSGD-1024x545.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01080649/AUDSGD-300x160.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01080649/AUDSGD-768x409.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01080649/AUDSGD.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
AUD/SGD daily chart, Source: TradingView
Still, the key level to observe is at 0.83420. If the price clears this level and closes above it on the daily chart, it may provide bullish opportunities on pullbacks, with a short-term potential to reach 0.84430.
<h3 class="wp-block-heading">2. NZD JPY</h3>
This pair spent the entire month in a relatively tight range, but has been building a base for the next breakout with a bullish bias. The key resistance level to watch is 88, and a clean break above the daily could signal a move higher toward the next resistance at 89.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="542" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01080700/NZDJPY-1024x542.png" alt="" class="wp-image-15127" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01080700/NZDJPY-1024x542.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01080700/NZDJPY-300x159.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01080700/NZDJPY-768x406.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01080700/NZDJPY.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
NZD/JPY daily chart, Source: TradingView
<h3 class="wp-block-heading">Notes:</h3>
<ul class="wp-block-list">
<li>AUD NZD: Failed to sustain a bullish breakout, but the support at 1.07750 held. If it cannot break this support, it might remain in the range.</li>
<li>AUD CAD: Swept the lows on Monday, before turning around and making an attempt at previous swing highs. However, it failed to sustain the impulse move, closing below the resistance of 0.89500.</li>
<li>AUD CHF: Remains in a bearish trend. Still, it has not yet decisively closed below the previous swing low around 0.52100.</li>
<li>AUD JPY:  Price action is tightening, indicating that a breakout might be on the cards soon. Short-term potential is higher to the upside if it overcomes the resistance at 94.800.</li>
<li>CHF JPY:  Reached the 180 target for the previous breakout and exceeded, going as high as 181. No signs of weakness for now.</li>
<li>CAD JPY: Indecisive price action, as it made a push higher and lower simultaneously. Short-term bias is tilting to the upside.</li>
<li>EUR AUD: Remains in a bullish trend, and has reached intermediate highs from April.</li>
<li>EUR/JPY: Established yet another yearly high, overcoming the short-term resistance at 169.270.</li>
<li>EUR NZD: A temporary resistance level around 1.94880 has held the short-term bullish push.</li>
<li>NZD CHF: Remains in a bearish trend, but found support around 0.48200.</li>
<li>GBP AUD: Remains in the bullish trend, but it is failing to breach the multi-month resistance at 2.10250</li>
<li>GBP JPY: Made fresh highs, but failed at the first attempt to breach 198.800. The trend remains bullish.</li>
</ul>
Disclaimer: Any opinions expressed in this article are not to be considered investment advice and are solely those of the authors. Singapore Forex Club is not responsible for any financial decisions based on this article&#8217;s contents. We provide research and promote <a href="https://singaporeforexclub.com/how-to-start-trading-forex-in-singapore" target="_blank" rel="noreferrer noopener">forex trading in Singapore</a>, and readers may use this data for information and educational purposes only.

Forex

Geopolitics Takes A Step Back As Central Bank Leaders Step Forward

<a href="https://europeancapitalinsights.substack.com/p/france-loses-niger-uranium-mine-as?r=3nmatg">France lost a strategic uranium</a> mine in Africa after Niger's military junta <a href="https://www.aljazeera.com/news/2025/6/20/niger-nationalises-uranium-mine-as-spat-with-french-nuclear-giant-worsens" target="_blank" rel="noreferrer noopener">seize</a>d the reserve from Europe&#8217;s biggest nuclear producer.
The junta described the nationalization of the Somair mine as "healthier and more sustainable management" of national resources. French state-owned company Orano SA had operated the mine for 55 years.
Niger&#8217;s uranium has fueled over 30% of France's nuclear reactors, making the seizure of Somair a strategic setback for Paris. Niger ranked among the world's top 10 uranium-rich nations, with <a href="https://world-nuclear.org/information-library/nuclear-fuel-cycle/mining-of-uranium/world-uranium-mining-production">6.2% of global reserves </a>in 2023.
Other regional governments have pressured foreign producers to surrender a higher percentage of royalty payments. Commodities have undergone sustained price increases starting started with gold surging above $2,400 per ounce in early 2024)
In Mali, the governing junta placed Barrick Mining's Loulo-Gounkoto complex <a href="https://www.benzinga.com/markets/commodities/25/06/45969041/barricks-top-gold-mine-placed-under-state-control" target="_blank" rel="noreferrer noopener">under state administration</a>. The government halted output in January at the complex that produces 600,000 ounces of gold annually after a tax dispute. The junta claimed it had secured over €1 billion in additional revenue by renegotiating mining contracts.
This pattern of abrupt regulatory changes has weakened the influence of France and Europe in the Sahel region. Russia and Turkey have expanded their ties, driven anti-Western sentiment and military coups in Mali, Burkina Faso, and Niger.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/$s_!5_yA!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F288aca99-50a9-4cc6-a752-34c4f4d04ce8_482x324.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/$s_!5_yA!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F288aca99-50a9-4cc6-a752-34c4f4d04ce8_482x324.png" alt="" /></a><figcaption class="wp-element-caption">Source: <a target="_blank" rel="noreferrer noopener" href="https://theconversation.com/sahel-region-africa-72569">The Conversation</a></figcaption></figure>
Côte d'Ivoire and Namibia may become uranium hubs as Western mining companies reassess their presence,
<h2 class="wp-block-heading">US Policies Revive Uranium Market</h2>
Uranium prices have increased over 11% to $79.70 per pound in June. After bottoming on April 8, Sprott Junior Uranium ETF (URNJ) rose by 74% on renewed investor confidence and robust demand.
Washington policymakers have provided significant tailwinds. On May 23, President Donald Trump signed&nbsp;<a href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-reinvigorates-the-nuclear-industrial-base/" target="_blank" rel="noreferrer noopener">four executive orders</a>&nbsp;invoking the Defense Production Act. This will accelerate domestic uranium production, enrichment, and fuel cycle infrastructure.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/$s_!FsrT!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6efe5a52-ddd6-480c-b85f-51e8da008ebf_1069x536.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/$s_!FsrT!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6efe5a52-ddd6-480c-b85f-51e8da008ebf_1069x536.png" alt="" /></a></figure>
Uranium spot price per pound, Source: <a target="_blank" rel="noreferrer noopener" href="https://tradingeconomics.com/commodity/uranium">TradingEconomics</a>
Trump&#8217;s executive orders aim to quadruple US nuclear power capacity from 100 GW to 400 GW by 2050. Annual uranium demand could increase from 50 million pounds to 200 million pounds U₃O₈. UxC said this is nearly double the 164 million pounds forecasted production for 2025. 
AI data centers have become major energy consumers. Meta's recent <a href="https://www.cnbc.com/2025/06/03/meta-signs-nuclear-power-deal-with-constellation-energy-.html" target="_blank" rel="noreferrer noopener">1.121 MW nuclear power deal</a> with Constellation Energy shows the scope of such requests. This combination of industrial and geopolitical momentum is positioning uranium as a cornerstone solution for the ever-growing energy demand.
After stagnating for two decades, EIA expects the U.S. power consumption to reach record highs in 2025 and 2026. Trump&#8217;s executive order will benefit Cameco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>), Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>), and GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>).
<h2 class="wp-block-heading">EU Commits €241 Billion to Nuclear Expansion</h2>
Like the US, the European Union (EU) has implemented policies to expand nuclear production.
The European Commission <a href="https://energy.ec.europa.eu/topics/nuclear-energy/nuclear-investment-needs_en">said</a> EU needs €241 billion to increase nuclear capacity from 98 GW to 109 GW by 2050. This includes €205 billion for the development of new reactors and €36 billion for the life extension of existing infrastructure.
Nuclear power currently supplies 23.7% of the EU's electricity. Twelve of the EU's 27 member states operate nuclear reactors. France&#8217;s 56 reactors account for approximately 70% of the EU&#8217;s nuclear capacity.
The commission has acknowledged the risks of delay. A five-year lag in new builds could result in increased costs of €45 billion. Rapid data center expansion is already straining the power grids of EU countries and limiting the potential for AI expansion. Ireland's data centers will consume <a href="https://www.merciaai.com/post/will-europe-s-ai-ambitions-succeed-part-2-the-energy-hungry-ai-boom" target="_blank" rel="noreferrer noopener">30% of the country's electricity</a> by 2030.
<h2 class="wp-block-heading">Western Europe Sees Nuclear Power Reassessed</h2>
The European Investment Bank plans to launch a <a href="https://www.eib.org/en/press/news/eib-group-and-european-commission-simplify-application-of-state-aid-rules-to-support-europe-s-clean-industry-and-hold-roundtable-with-business-leaders" target="_blank" rel="noreferrer noopener">€500 million pilot program</a> for power purchase agreements, with nuclear projects. The Commission pointed out that "a combination of diverse sources of financing complemented by de-risking instruments may be the response."
Recent political shifts support this transition. Germany changed its policy after shutting down of its last three nuclear reactors in 2023. It stopped hindering the inclusion of nuclear energy in the EU&#8217;s green energy initiatives. Denmark and Spain have reevaluated their positions on nuclear energy, prompted by concerns over energy security and recent grid disruptions.
Europe has started to reassess its nuclear energy powers, seeing is crucial. Urenco Group, a uranium-enrichment company majority-owned by the Netherlands and the UK, could benefit from this market shift.
&#8220;We know that it&#8217;s a low-carbon energy source,&#8221; Belgium&#8217;s Energy Minister Mathieu Bihet <a href="https://www.euronews.com/my-europe/2025/05/27/why-nuclear-energy-is-making-a-comeback-across-europe" target="_blank" rel="noreferrer noopener">said</a>. &#8220;It&#8217;s also an abundant energy source.&#8221; 

<h3 class="wp-block-heading">Sweden&#8217;s Viken Uranium Deposit Is European Game-Changer</h3>
The Swedish Ministry of Climate and Enterprise proposed on June 12 to lift the country&#8217;s uranium mining ban. If the parliament ratifies the proposal, uranium will be classified as a concession mineral under the Minerals Act, effective January 1, 2026.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="723" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01104614/image-1024x723.png" alt="" class="wp-image-15145" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01104614/image-1024x723.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01104614/image-300x212.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01104614/image-768x542.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01104614/image.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Uranium concentration in the soil of Europe, Source: <a target="_blank" rel="noreferrer noopener" href="https://remon.jrc.ec.europa.eu/About/Atlas-of-Natural-Radiation/Digital-Atlas/Uranium-in-soil/Uranium-concentration-in-soil-">EU Joint Research Centre</a>
The Canadian mining company District Metals Corp (DMXCF: OTCQB) would benefit from this policy change. Its <a href="https://districtmetals.com/projects/viken-sweden/" target="_blank" rel="noreferrer noopener">Viken Property</a> in central Sweden has 43,500 tons (95.9 million pounds) of U₃O₈. According to the company&#8217;s filings and independent assessments, this deposit represents more than 80% of Europe's known uranium resources.
The deposit includes major quantities of vanadium (312 million pounds), molybdenum (144 million pounds), and nickel (98 million pounds).
"The Swedish Government's consistent and rigorous approach toward lifting the uranium moratorium appears to be advancing… Sweden is poised to unlock its vast uranium resources for the green energy transition during a time of increasing geopolitical unrest," CEO Garrett Ainsworth said in <a target="_blank" rel="noreferrer noopener" href="https://districtmetals.com/news/2025/district-comments-on-uranium-mining-announcement-from-the-swedish-government-3/">the latest statement</a>.
The firm has commenced an <a href="https://districtmetals.com/news/2025/district-completes-airborne-mobilemt-survey-at-the-viken-property-and-commences-mobilemt-at-the-alum-shale-properties-in-sweden/" target="_blank" rel="noreferrer noopener">airborne MobileMT geophysical survey</a>. It updated the Viken resource model as of April 2025, guaranteeing readiness for permitting and future production once the moratorium is lifted. 
Sweden&#8217;s foray into uranium production could potentially mitigate Europe&#8217;s supply risks following disruptions in Niger and the tense relations with Russia, which accounts for over 20% of the EU&#8217;s enriched uranium supply.
Disclaimer:
Any opinions expressed in this article are not to be considered investment advice and are solely those of the authors. European Capital Insights is not responsible for any financial decisions made based on the contents of this article. Readers may use this article for information and educational purposes only.&nbsp;
This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.

Comments

Avenue Therapeutics

Avenue Therapeutics (ATXI) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL